Successful osimertinib rechallenge without concomitant corticosteroids after osimertinib-induced pneumonitis.

Abstract

A 60-year-old woman was diagnosed with cT4N3M1c stage IVB lung adenocarcinoma with epidermal growth factor receptor mutation of exon19 deletion. After one month of treatment with osimertinib, a cough and diffuse ground glass opacities were observed in the bilateral lung field. Based on the clinical course and the exclusion of other etiologies, osimertinib-induced pneumonitis was diagnosed. The shadows resolved after osimertinib was discontinued. However, brain metastasis and leptomeningeal metastasis developed 20 months later; therefore, osimertinib was re-administered without concomitant corticosteroids. The pulmonary lesion and leptomeningeal metastasis were successfully treated without recurrence of drug-induced pneumonitis for eight months.

• Authors: Taisuke Ito, Kazuo Tsuchiya, Rie Mori, Takuro Akashi, Yoshiyuki Oyama, Masaki Ikeda
• Journal: Respiratory medicine case reports (Respir Med Case Rep) Vol. 49 Pg. 102029 ( 2024) ISSN: 2213-0071 [Print] England
• PMID: 38712314 (Publication Type: Case Reports)
• Copyright: © 2024 The Authors. Published by Elsevier Ltd.